PHARMACEUTICAL PREPARATIONS – Page 224

SVA [SINOVAC BIOTECH] 6-K: Sinovac Receives China’s First Influenza A (H1N1) Vaccine

[Sinovac Receives China's First Influenza A (H1N1) Vaccine Order BEIJING, June 19 /PRNewswire-Asia/ -- Sinovac Biotech Ltd. (NYSE Amex: SVA), a leading developer and provider of vaccines in China, announced today that the Company received the first order in China to supply its influenza A (H1N1) vaccine to the Beijing government. The initial order consists of 4 million doses and] [FORM 6-K __________ __________ SINOVAC BIOTECH LTD. 39 Shangdi Xi Road Haidian District Beijing 100085, People’s Republic of China X Form 20-F X Yes _______ No N/A 82- SINOVAC BIOTECH LTD. Form 6-K TABLE OF CONTENTS Page 3 4]

By info| 2016-03-24T05:09:14+00:00 August 27th, 2009|Categories: Chinese Stocks, SVA, Webplus ver|Tags: 0001084201, 2009-08-27, 2834, 6-K, PHARMACEUTICAL PREPARATIONS, SVA|0 Comments

SVA [SINOVAC BIOTECH] 6-K: (Original Filing)

[SINOVAC REPORTS TOP-LINE PRELIMINARY RESULTS OF H1N1 VACCINE CLINICAL TRIALS - Results Show Good Safety Profile and Immunogenicity - BEIJING, Aug. 18 /PRNewswire-Asia/ -- Sinovac Biotech Ltd. (NYSE Amex: SVA), a leading provider of vaccines in China, announced today positive top-line results from the completed clinical trial for its internally-developed H1N1 vaccine. The clinical data unblinding conference was held in] [FORM 6-K __________ __________ SINOVAC BIOTECH LTD. 39 Shangdi Xi Road Haidian District Beijing 100085, People’s Republic of China X Form 20-F X Yes _______ No N/A 82- SINOVAC BIOTECH LTD. Form 6-K TABLE OF CONTENTS Page 3 4]

By info| 2016-03-24T04:48:59+00:00 August 27th, 2009|Categories: Chinese Stocks, SEC Original, SVA|Tags: 0001084201, 2009-08-27, 2834, 6-K, PHARMACEUTICAL PREPARATIONS, SVA|0 Comments

SVA [SINOVAC BIOTECH] 6-K: SINOVAC REPORTS TOP-LINE PRELIMINARY RESULTS OF H1N1 VACCINE

[SINOVAC REPORTS TOP-LINE PRELIMINARY RESULTS OF H1N1 VACCINE CLINICAL TRIALS - Results Show Good Safety Profile and Immunogenicity - BEIJING, Aug. 18 /PRNewswire-Asia/ -- Sinovac Biotech Ltd. (NYSE Amex: SVA), a leading provider of vaccines in China, announced today positive top-line results from the completed clinical trial for its internally-developed H1N1 vaccine. The clinical data unblinding conference was held in] [FORM 6-K __________ __________ SINOVAC BIOTECH LTD. 39 Shangdi Xi Road Haidian District Beijing 100085, People’s Republic of China X Form 20-F X Yes _______ No N/A 82- SINOVAC BIOTECH LTD. Form 6-K TABLE OF CONTENTS Page 3 4]

By info| 2016-03-24T04:50:07+00:00 August 27th, 2009|Categories: Chinese Stocks, SVA, Webplus ver|Tags: 0001084201, 2009-08-27, 2834, 6-K, PHARMACEUTICAL PREPARATIONS, SVA|0 Comments

SVA [SINOVAC BIOTECH] 6-K: (Original Filing)

[Sinovac to Host Conference Call to Report 2009 Second Quarter Financial Results BEIJING, Aug. 11 /PRNewswire-Asia/ -- Sinovac Biotech Ltd. (NYSE Amex: SVA), a leading provider of vaccines in China, today announced that it will host a conference call on Wednesday, August 19, 2009 at 8:00 a.m. ET to review the Company's second quarter financial results for the period ended] [FORM 6-K __________ __________ SINOVAC BIOTECH LTD. 39 Shangdi Xi Road Haidian District Beijing 100085, People’s Republic of China X Form 20-F X Yes _______ No N/A 82- SINOVAC BIOTECH LTD. Form 6-K TABLE OF CONTENTS Page 3 4]

By info| 2016-03-24T04:51:30+00:00 August 27th, 2009|Categories: Chinese Stocks, SEC Original, SVA|Tags: 0001084201, 2009-08-27, 2834, 6-K, PHARMACEUTICAL PREPARATIONS, SVA|0 Comments

SVA [SINOVAC BIOTECH] 6-K: Sinovac to Host Conference Call to Report 2009

[Sinovac to Host Conference Call to Report 2009 Second Quarter Financial Results BEIJING, Aug. 11 /PRNewswire-Asia/ -- Sinovac Biotech Ltd. (NYSE Amex: SVA), a leading provider of vaccines in China, today announced that it will host a conference call on Wednesday, August 19, 2009 at 8:00 a.m. ET to review the Company's second quarter financial results for the period ended] [FORM 6-K __________ __________ SINOVAC BIOTECH LTD. 39 Shangdi Xi Road Haidian District Beijing 100085, People’s Republic of China X Form 20-F X Yes _______ No N/A 82- SINOVAC BIOTECH LTD. Form 6-K TABLE OF CONTENTS Page 3 4]

By info| 2016-03-24T04:52:46+00:00 August 27th, 2009|Categories: Chinese Stocks, SVA, Webplus ver|Tags: 0001084201, 2009-08-27, 2834, 6-K, PHARMACEUTICAL PREPARATIONS, SVA|0 Comments

SVA [SINOVAC BIOTECH] 6-K: (Original Filing)

[REVISED: SINOVAC PROVIDES UPDATE ON CLINICAL TRIAL FOR H1N1 VACCINE TRIALS -H1N1 Vaccine Shows Good Safety Profile- BEIJING, Aug. 4 /PRNewswire-Asia/ -- Sinovac Biotech Ltd. (NYSE AMEX: SVA), a leading provider of vaccines in China, announced today that the clinical trial of its A/H1N1 influenza vaccine is proceeding well. All of the volunteers received their first shot of the vaccine] [FORM 6-K __________ __________ SINOVAC BIOTECH LTD. 39 Shangdi Xi Road Haidian District Beijing 100085, People’s Republic of China X Form 20-F X Yes _______ No N/A 82- SINOVAC BIOTECH LTD. Form 6-K TABLE OF CONTENTS Page 3 4]

By info| 2016-03-24T04:54:28+00:00 August 27th, 2009|Categories: Chinese Stocks, SEC Original, SVA|Tags: 0001084201, 2009-08-27, 2834, 6-K, PHARMACEUTICAL PREPARATIONS, SVA|0 Comments

SVA [SINOVAC BIOTECH] 6-K: REVISED: SINOVAC PROVIDES UPDATE ON CLINICAL TRIAL FOR

[REVISED: SINOVAC PROVIDES UPDATE ON CLINICAL TRIAL FOR H1N1 VACCINE TRIALS -H1N1 Vaccine Shows Good Safety Profile- BEIJING, Aug. 4 /PRNewswire-Asia/ -- Sinovac Biotech Ltd. (NYSE AMEX: SVA), a leading provider of vaccines in China, announced today that the clinical trial of its A/H1N1 influenza vaccine is proceeding well. All of the volunteers received their first shot of the vaccine] [FORM 6-K __________ __________ SINOVAC BIOTECH LTD. 39 Shangdi Xi Road Haidian District Beijing 100085, People’s Republic of China X Form 20-F X Yes _______ No N/A 82- SINOVAC BIOTECH LTD. Form 6-K TABLE OF CONTENTS Page 3 4]

By info| 2016-03-24T04:55:33+00:00 August 27th, 2009|Categories: Chinese Stocks, SVA, Webplus ver|Tags: 0001084201, 2009-08-27, 2834, 6-K, PHARMACEUTICAL PREPARATIONS, SVA|0 Comments

BSPM [Biostar Pharmaceuticals,] 8-K: (Original Filing)

[BIOSTAR PHARMACEUTICALS, INC. ANNOUNCES SECOND QUARTER 2009 FINANCIAL RESULTS Second Quarter 2009 Revenue Increased 40.6% to Approximately $13.2 Million and Net Income Increased 119.3% to Approximately $3.9 Million with EPS of $0.17 Gross Margins Improved 1630-Basis Points to 73.5% over Q2 2008 Press Release Source: Biostar Pharmaceuticals, Inc. On Friday August 14, 2009, 7:30 am EDT BSPM News ; XIANYANG,] [BIOSTAR PHARMACEUTICALS, INC. TO HOST FISCAL YEAR 2009 SECOND QUARTER EARNINGS CONFERENCE CALL ON FRIDAY, AUGUST 14, 2009 AT 10:30 A.M. EDT Press Release Source: Biostar Pharmaceuticals, Inc. On Wednesday August 12, 2009, 7:30 am EDT BSPM News ; XIANYANG, China, Aug. 12 /PRNewswire-Asia-FirstCall/ -- Biostar Pharmaceuticals, Inc. (OTC Bulletin Board: http://www.viavid.net http://viavid.net/dce.aspx?sid=00006906 http://www.microsoft.com/windows/windowsmedia/en/download/default.asp This call is being web cast]

By info| 2016-03-03T15:50:50+00:00 August 18th, 2009|Categories: BSPM, Chinese Stocks, SEC Original|Tags: 0001418133, 2009-08-18, 2834, 8-K, BSPM, PHARMACEUTICAL PREPARATIONS|0 Comments

BSPM [Biostar Pharmaceuticals,] 8-K: BIOSTAR PHARMACEUTICALS, INC. ANNOUNCES SECOND QUARTER 2009 FINANCIAL

[BIOSTAR PHARMACEUTICALS, INC. ANNOUNCES SECOND QUARTER 2009 FINANCIAL RESULTS Second Quarter 2009 Revenue Increased 40.6% to Approximately $13.2 Million and Net Income Increased 119.3% to Approximately $3.9 Million with EPS of $0.17 Gross Margins Improved 1630-Basis Points to 73.5% over Q2 2008 Press Release Source: Biostar Pharmaceuticals, Inc. On Friday August 14, 2009, 7:30 am EDT BSPM News ; XIANYANG,] [BIOSTAR PHARMACEUTICALS, INC. TO HOST FISCAL YEAR 2009 SECOND QUARTER EARNINGS CONFERENCE CALL ON FRIDAY, AUGUST 14, 2009 AT 10:30 A.M. EDT Press Release Source: Biostar Pharmaceuticals, Inc. On Wednesday August 12, 2009, 7:30 am EDT BSPM News ; XIANYANG, China, Aug. 12 /PRNewswire-Asia-FirstCall/ -- Biostar Pharmaceuticals, Inc. (OTC Bulletin Board: http://www.viavid.net http://viavid.net/dce.aspx?sid=00006906 http://www.microsoft.com/windows/windowsmedia/en/download/default.asp This call is being web cast]

By info| 2016-03-03T15:52:04+00:00 August 18th, 2009|Categories: BSPM, Chinese Stocks, Webplus ver|Tags: 0001418133, 2009-08-18, 2834, 8-K, BSPM, PHARMACEUTICAL PREPARATIONS|0 Comments

SKBI [SKYSTAR BIO-PHARMACEUTICAL CO] 10-Q: (Original Filing)

[FORM 10-Q þ For the quarterly period ended June 30, 2009 or o For the transition period from Skystar Bio-Pharmaceutical Company (Exact name of small business issuer as specified in its charter) Nevada (State or other jurisdiction of incorporation or organization) 33-0901534 (I.R.S. employer identification number) Room 10601, Jiezuo Plaza, No.4, Fenghui Road South, Gaoxin District, Xian Province, P.R. China] [CERTIFICATION I, Weibing Lu, certify that: 1. I have reviewed this Quarterly 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period] [CERTIFICATION I, Bennet T. Tchaikovsky, certify that: 1. I have reviewed this Quarterly 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the] [CERTIFICATION (1) (2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company at the dates and for the periods indicated. Weibing Lu Weibing Lu Chief Executive Officer EX-32.1 5 v156959_ex32-1.htm] [CERTIFICATION (1) (2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company at the dates and for the periods indicated. Bennet P. Tchaikovsky Chief Financial Officer (Principal Financial and Accounting Officer) EX-32.2 6 v156959_ex32-2.htm]

By info| 2016-03-01T07:23:01+00:00 August 14th, 2009|Categories: Chinese Stocks, SEC Original, SKBI|Tags: 0001076939, 10-Q, 2009-08-14, 2834, PHARMACEUTICAL PREPARATIONS, SKBI|0 Comments